Detalhe da pesquisa
1.
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1458-1467, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34543613
2.
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
BMC Med
; 17(1): 207, 2019 11 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31747948
3.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 474-485, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29482983
4.
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program.
Curr Oncol
; 29(9): 6635-6641, 2022 09 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36135090
5.
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.
Clin Cancer Res
; 28(2): 308-317, 2022 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34667023
6.
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Cells
; 11(19)2022 10 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36231138
7.
A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study.
Diagnostics (Basel)
; 11(6)2021 May 28.
Artigo
Inglês
| MEDLINE | ID: mdl-34071518
8.
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
Eur J Cancer
; 154: 21-29, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34225066
9.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Breast Care (Basel)
; 15(1): 30-37, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32231495
10.
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(94): 36720-36721, 2018 11 30.
Artigo
Inglês
| MEDLINE | ID: mdl-30613355
11.
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(61): 31877-31887, 2018 08 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30159129
12.
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Oncotarget
; 9(77): 34639-34640, 2018 10 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30349655
13.
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
Oncologist
; 12(7): 766-73, 2007 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-17673608